Clinical roundtable monograph. Combination therapies for MDS.
Scott
Bart L
BL
University of Washington Medical Center, Seattle, WA, USA.
D001374:Azacitidine / Q000008:administration & dosage; D002352:Carrier Proteins / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D000068800:Etanercept; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D007074:Immunoglobulin G / Q000008:administration & dosage; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D017713:Platelet Transfusion; D011961:Receptors, Fc / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D013926:Thrombopoietin; D014635:Valproic Acid / Q000008:administration & dosage; D000077337:Vorinostat
D002352:Carrier Proteins; D003115:Colony-Stimulating Factors; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D007074:Immunoglobulin G; D011961:Receptors, Fc; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D013792:Thalidomide; D000077337:Vorinostat; D014635:Valproic Acid; D013926:Thrombopoietin; D000077269:Lenalidomide; C488777:romiplostim; D001374:Azacitidine; D000068800:Etanercept